Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder

New England Journal of Medicine

Volumn 381, Issue 7, 2019, Pages 614-625

  Pittock, S J ^a   Berthele, A ^b   Fujihara, K ^c,e,f   Kim, H J ^g   Levy, M ^h,i   Palace, J ^k   Nakashima, I ^c,d   Terzi, M ^l   Totolyan, N ^m   Viswanathan, S ⁿ   Wang, K C ^o   Pace, A ^j   Fujita, K P ^j   Armstrong, R ^j   Wingerchuk, D M ^p  

^a MAYO CLINIC   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^e FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^f Southern Tohoku General Hospital and Southern Tohoku Research Institute for Neuroscience   (Japan)

^g National Cancer Center   (South Korea)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j ALEXION PHARMACEUTICALS   (United States)

^k JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^l ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^m PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

ⁿ HOSPITAL KUALA LUMPUR   (Malaysia)

^o NATIONAL YANG MING UNIVERSITY   (Taiwan)

^p MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; ECULIZUMAB; PLACEBO; AUTOANTIBODY; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HEADACHE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; NAUSEA; OUTCOME ASSESSMENT; PLEURA EMPYEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; TREATMENT PLANNING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISABILITY; DISEASE EXACERBATION; IMMUNOLOGY; PHASE 3 CLINICAL TRIAL; RESPIRATORY TRACT INFECTION; SECONDARY PREVENTION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; AUTOANTIBODIES; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUROMYELITIS OPTICA; QUALITY OF LIFE; RESPIRATORY TRACT INFECTIONS; SECONDARY PREVENTION;

EID: 85068217218     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1900866     Document Type: Article

References (29)

1. Papp V, Illes Z, Magyari M, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 2018; 91(24): e2265-e2275.
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-14.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-15.
4. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc 2017; 92: 663-79.
5. Kitley J, Leite MI, Elsone L, Jacob A, Palace J. Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials. J Neurol Neurosurg Psychiatry 2014; 85: 589-90.
6. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 2016; 18: 2.
7. Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016; 22: 329-39.
8. Frigeri A, Gropper MA, Umenishi F, Kawashima M, Brown D, Verkman AS. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci 1995; 108: 2993-3002.
9. He D, Zhang A, Li Y, Cai G, Li Y, Guo S. Autoimmune aquaporin-4 induced damage beyond the central nervous system. Mult Scler Relat Disord 2017; 18: 41-6.
10. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81: 1197-204.
11. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016; 87: 1005-15.
12. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109: 1245-50.
13. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intracerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133: 349-61.
14. Duan T, Smith AJ, Verkman AS. Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 2018; 15: 294.
15. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and singlechain Fv. Mol Immunol 1996; 33: 1389-401.
16. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12: 554-62.
17. World Medical Association. WMA Declaration of Helsinki-ethical principles for medical research involving human subjects. Ferney-Voltaire, France: World Medical Association, October 2013 (https://www.wma .net/ policies-post/ wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ ).
18. International Conference on Harmonisation. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47: 45-50.
19. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
21. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7.
22. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis-a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 1983; 308: 173-80.
23. EuroQol Research Foundation. EQ-5D-3L user guides. Rotterdam, the Netherlands: EuroQol Research Foundation, 2018 (https://euroqol .org/ publications/ user-guides).
24. Dmitrienko A, D'Agostino RB Sr. Multiplicity considerations in clinical trials. N Engl J Med 2018; 378: 2115-22.
25. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264: 2003-9.
26. Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011; 186: 3762-9.
27. Soliris: product information. London: European Medicines Agency, 2018 (https://www.ema .europa .eu/ en/ medicines/ human/ EPAR/ soliris#product-information-section).
28. Soliris (eculizumab) prescribing information: injection for intravenous use. Silver Spring, MD: Food and Drug Administration, 2018 (https://www.accessdata .fda.gov/drugsatfda-docs/ label/ 2018/ 125166s047s048lbl .pdf).
29. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177-89.